Invirase (saquinavir mesylate)
Hoffmann-La Roche Limited, in consultation with Health Canada, would like to inform healthcare professionals of important new safety information regarding the use of INVIRASE® (saquinavir mesylate) and significant dose-dependent prolongations of QT and PR intervals in healthy volunteers.
INVIRASE is authorized for the treatment of HIV-1 infected adult patients. INVIRASE should only be given in combination with ritonavir and other antiretroviral medicinal products.
Saquinavir ATC Code: J05AE01 INVIRASE is authorized for the treatment of HIV-1 infected adult patients. INVIRASE should only be given in combination with ritonavir and other antiretroviral medicinal products.
No comments:
Post a Comment